Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | PDE2A | O00408 | 3/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12058638 | 1.00 | IDO1 (0.41) | IDO1PDE2AARRORCSLC6A2 | |
| SCHEMBL21725488 | 0.86 | IDO1 (0.39) | IDO1PDE2ARORCSLC6A2SLC6A4 | |
| SCHEMBL19405219 | 0.86 | SLC6A2 (0.41) | IDO1PDE2AARRORCSLC6A2 | |
| SCHEMBL21725492 | 0.84 | IDO1 (0.42) | IDO1PDE2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2759872 | 0.82 | AR (0.40) | PDE2AARRORCSLC6A2TSHR | |
| SCHEMBL26619829 | 0.81 | DPP4 (0.43) | IDO1PDE2AARSLC6A2SLC6A4 | |
| SCHEMBL6815689 | 0.81 | DPP4 (0.43) | IDO1PDE2AARSLC6A2SLC6A4 | |
| SCHEMBL4547922 | 0.81 | NOTUM (0.44) | IDO1PDE2AARRORCSLC6A2 | |
| SCHEMBL21725462 | 0.81 | AR (0.39) | PDE2AARRORCTSHRP2RX7 | |
| Hydrochloric Acid SCHEMBL14121597 | 0.80 | IDO1 (0.45) | IDO1PDE2AARSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-08-24 | — | — | US | disclosed |
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210238164-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210002254-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-01-07 | — | — | US | disclosed |
| US-20200216415-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-07-09 | — | — | US | disclosed |
| US-10604507-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-31 | — | — | US | disclosed |
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10308652-B2 | Tricyclic heterocyclic compounds useful as inhibitors of TNF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180111937-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TNF | BRISTOL MYERS SQUIBB CO (US) | 2018-04-26 | — | — | US | disclosed |
| US-20110319411-A1 | ISOINDOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTIS PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | IDO1 782/4885PDE2A 1206/4885AR 413/4885 |
| US-20210238164-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | IDO1 782/4885PDE2A 1206/4885AR 413/4885 |
| US-10604507-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | IDO1 782/4885PDE2A 1206/4885AR 413/4885 |
| US-20180111937-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TNF | TNF, TNFRSF1A, TNFRSF9 | IDO1 584/4885PDE2A 769/4885AR 2068/4885 |
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | IDO1 782/4885PDE2A 1206/4885AR 413/4885 |
| US-10308652-B2 | Tricyclic heterocyclic compounds useful as inhibitors of TNF | TNF, TNFRSF1A, TNFRSF9 | IDO1 584/4885PDE2A 769/4885AR 2068/4885 |
| US-20210002254-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | IDO1 782/4885PDE2A 1206/4885AR 413/4885 |
| US-20200216415-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | IDO1 782/4885PDE2A 1206/4885AR 413/4885 |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | STAT5B, STAT5A, STAT3 | IDO1 2315/4885PDE2A 1199/4885AR 1616/4885 |
| US-20110319411-A1 | ISOINDOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | IDO1 310/4885PDE2A 1347/4885AR 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.